Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Sector Health Care/Life Sciences. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. For the best MarketWatch.com experience, please update to a modern browser. Find the latest Exicure, Inc. (XCUR) stock quote, history, news and other vital information to help you with your stock trading and investing. Suite 410. Fiscal Year-end 12/2020. XCUR 2.59 0.07 (2.78%). All rights reserved. The stock traded as low as $2.00 and last traded at $2.07. How has Exicure's share price performed over time and what events caused price changes? -0.16 (-7.17%) DATA AS OF Mar 04, 2021. Post-Market 0.00 (0.00%) XCUR stock closed at $1.58 and is up $0.50 during pre-market trading. Latest Share Price and Events Stable Share Price : XCUR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week. Exicure started at outperform with $6 stock price target at BMO Capital. Contact IR; FAQs; Email Alerts Biopharmaceutical concern Exicure strengthened its balance sheet with two secondary offerings and two partnership deals in 2019. 1,386,118 shares changed hands during mid-day trading, an increase of 134% from the average session volume of 592,617 shares. View the latest Exicure Inc. (XCUR) stock price, news, historical charts, analyst ratings and financial information from WSJ. Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Interactive Financials; Financial Summary; SEC Filings; Annual Reports; Governance. Cookie Notice (). Time to Start Paying Down Debt, Uncle Sam, 2 Stocks With Earnings Growth Beyond 2021, Bond Vigilantes Are Back, but Unlikely to Cause a New Black Monday for Stocks, Global Emphasis on February 2, 2021 - 7:00 am. Exicure is based outside of Chicago, IL and in Cambridge, MA. Add to Portfolio. Phone 1 847 673-1700. Cool Trend for Trane, Exicure started at outperform with $6 stock price target at BMO Capital, Ex-Trump lawyer Cohen asks for early release from his home confinement, Exicure shares rise on immuno-oncology trial, Exicures shares up on Allergan partnership, H.C. Wainwright Reiterates a Buy Rating on Exicure (XCUR), Chardan Capital Remains a Buy on Exicure (XCUR), Exicure, Inc. (XCUR) Reports Q4 Loss, Misses Revenue Estimates, Analysts’ Top Services Picks: Exicure (XCUR), Comcast (CMCSA), Analysts’ Top Services Picks: Exicure (XCUR), Wendy’s (WEN), Exicure, Inc. (XCUR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release, Exicure (XCUR) Receives a Buy from H.C. Wainwright, Analysts Are Bullish on Top Services Stocks: Exicure (XCUR), fuboTV (FUBO), H.C. Wainwright Reiterates Their Buy Rating on Exicure (XCUR). Privacy Notice, and Copyright © 2021 MarketWatch, Inc. All rights reserved. Get prepared with the key expectations. EXICURE, INC. : News, information and stories for EXICURE, INC. | Nasdaq: XCUR | Nasdaq It uses spherical nucleic acid technology platform … Intraday data delayed at least 15 minutes or per exchange requirements. You can buy and sell Exicure (XCUR) stock and options and many more commission-free on Robinhood with real-time quotes, market data, and relevant news. Dec. 23, 2019- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $2.75 per share. News; Events & Presentations; Stock Info. Currency in USD, Trade prices are not sourced from all markets. Get the latest Exicure, Inc. (XCUR) stock news and headlines to help you in your trading and investment decisions. Industry Biotechnology. Shares of Exicure, Inc. (NASDAQ:XCUR) fell 7.2% during trading on Thursday . Revenue $1.3M. A high-level overview of Exicure, Inc. (XCUR) stock. Create a list of the investments you want to track. Exicure Inc NASDAQ Updated Mar 16, 2021 11:56 PM. Intraday Data provided by FACTSET and subject to terms of use. Stock Quote & Chart; Analyst Coverage; Financials. Executive Management; Board of Directors; Governance Documents; Committee Composition; Resources. Allergan, Exicure Strike Collaboration Agreement For Hair Loss Disorder Drugs. Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. View the latest ratings for XCUR. Exicure shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a $6 price target. Nasdaq 100. It is not uncommon to see companies perform well in the years after insiders buy shares. Exicure's cavrotolimod an Orphan Drug in U.S. for rare skin.. 3/03/2021: 07:00: BW: Exicure Granted Orphan Drug Designation by the U.S. Food and.. 2/23/2021: 07:00: BW: Exicure Announces Presentation at 2021 H.C. Wainwright.. 2/09/2021: 07:00: BW: Exicure … Have Watchlists? Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. Exicure currently has 5 buy ratings from Wall Street analysts. All quotes are in local exchange time. Historical and current end-of-day data provided by FACTSET. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. © 2021 Verizon Media. 2.4400 -0.01 (-0.41%)After hours: 7:49PM EDT. A "buy" rating indicates that analysts believe XCUR will outperform the market and that investors should add to their positions of Exicure. zoltansuranyi@benzinga.com Fri, 18 … Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Insider Ownership of Exicure . Something went wrong while loading Watchlist. Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA (TM)) constructs, today announced that David Giljohann, CEO, will present at the 2021 BIO CEO & Investor Digital Conference, February 16-18, 2021. With a … Cleaner Indoor Air Is Exicure, Inc. (XCUR) delivered earnings and revenue surprises of -50.00% and -95.33%, respectively, for the quarter ended December 2020. Exicure, Inc. (XCUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Stock analysis for Exicure Inc (XCUR:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Subscriber Agreement & Terms of Use, This browser is no longer supported at MarketWatch. Based on our data, Exicure insiders have about 3.1% of the stock, worth approximately US$4.8m. - Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones - Exicure to Host Conference Call Today at 8:30am ET/7:30am CT $2.07. Log in to see them here or sign up to get started. Summary. The stock has a consensus analyst rating of "Buy." Visit a quote page and your recently viewed tickers will be displayed here. Other stocks mentioned: AGN. By using this site you agree to the XCUR has a roughly average overall score of 47 meaning the stock holds a better value than 47% of stocks at its current price. Exicure Inc. 8045 Lamon Avenue. Exicure, Inc. Common Stock (XCUR) Nasdaq Listed. It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. Find real-time XCUR - Exicure Inc stock quotes, company profile, news and forecasts from CNN Business. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Exicure against related stocks people have also bought like TXMD, NMTR, AGTC, and GERN. Dec. 18, 2020 at 8:49 a.m. Exicure stock … Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA ™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Skokie, Illinois 60077. Exicure last month announced a deal with Allergan AGN, +0.06% in which the companies will develop treatments for hair loss disorders. Exicure's drug candidate AST-008 is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is focused on developing innovative medicines to treat diseases with known genetic basis. ET by Tomi Kilgore. Get the latest Exicure Inc (XCUR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Exicure, Inc. Common Stock (XCUR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Exicure Inc is a clinical-stage biotechnology company which develops a new class of immunomodulatory and gene silencing drugs against validated targets. Shares of the thinly traded micro-cap Exicure Inc (NASDAQ: XCUR) were advancing strongly Thursday in the wake of a collaboration agreement announced by the company with Allergan plc (NYSE: AGN). Do the numbers hold clues to what lies ahead for the stock? Since then, XCUR shares have increased by 53.0% and is now trading at $2.54. Find the latest Exicure, Inc. (XCUR) stock quote, history, news and other vital information to help you with your stock trading and investing. Add to Watchlist. Exicure received gross proceeds of $27.50 million from the sale of common stock in the offering, prior to deducting the underwriting discounts and … The stock had previously closed at $2.23. Several research firms have commented […] 12/28/2020 14:15 Here's Why Exicure (NASDAQ:XCUR) Can Manage Its Debt Despite Losing Money Data is currently not available. Our primary focus is on diseases that are amenable to our SNA technology with favorable clinical development pathways and clear, unmet medical need. Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA(TM)) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its clinical product candidate, cavrotolimod (AST-008), for the treatment of patients with Merkel cell carcinoma (MCC). Get the latest Exicure, Inc. (XCUR) stock news and headlines to help you in your trading and investing decisions. There are currently no items in this Watchlist. Get Exicure Inc (XCUR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Many investors like to check how much of a company is owned by insiders. Exicure's stock was trading at $1.66 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO).
Unturned Best Weapons, Corona-maßnahmen Hessen Aktuell, Volksbank Immobilien Herdorf, Wetter Tal Der Könige, Flieger Grüß Mir Die Sonne Youtube, Franken Bräu Produkte, Unfall Waldshut Heute, Wandavision Start Deutschland Uhrzeit, Kata Za Wilaya Ya Kwimba,